Group 1 - The core point of the news is that Hema Medical (希华医药) has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. and Hanmi Pharmaceutical Co., Ltd. for the antiviral drug encequidar, which Hema Medical holds exclusive global rights outside of South Korea [1] - Under the agreement, Hema Medical and Hanmi will grant Gilead exclusive global rights to encequidar in the field of virology, while also providing drug supply and sharing technical knowledge [1] - Hema Medical is set to receive an upfront payment of $10 million, with potential milestone payments reaching up to approximately $72.5 million, along with royalties based on a low single-digit percentage of net sales [1] Group 2 - Hema Medical is primarily focused on innovative drug development in the oncology field and is currently researching oral formulations of paclitaxel combined with encequidar for the treatment of metastatic breast cancer [2] - The company is preparing to initiate a Phase 3 global clinical study for the oral paclitaxel and encequidar regimen for metastatic breast cancer, with plans to conduct the study at multiple centers in the United States, Hong Kong, and New Zealand by the end of 2025 [2]
希玛医疗(03309)：希华医药与Gilead及韩美就encequidar订立三方全球授权及合作协议